Baseline patient and ICI regimen characteristics (n=19)
| Characteristics | No. of patients |
| Age at irEnteritis, median (range) | 62 (29–86) |
| Female sex | 10 (53%) |
| Race | |
| White | 16 (84%) |
| Black | 1 (5%) |
| Other/unknown | 2 (11%) |
| Cancer type | |
| Melanoma | 6 (32%) |
| Lung | 5 (26%) |
| Genitourinary | 3 (16%) |
| Gynecologic | 2 (11%) |
| Hematologic | 1 (5%) |
| Breast | 1 (5%) |
| Angiosarcoma | 1 (5%) |
| Cancer stage | |
| I–III | 6 (32%) |
| IV | 13 (68%) |
| Cancer status | |
| Stable disease | 10 (52%) |
| Progressive disease | 3 (16%) |
| Partial response | 3 (16%) |
| Complete response | 3 (16%) |
| Concurrent chemotherapy | 2 (11%) |
| ICI regimen | |
| PD-(L)1 | 12 (63%) |
| CTLA-4 + PD-(L)1 | 7 (37%) |
| Total days on ICI therapy prior to irEnteritis, median (IQR) | 116 (57–151) |
| No. of ICI cycles prior to irEnteritis onset | |
| 1–2 | 6 (32%) |
| 3–5 | 4 (21%) |
| 6–10 | 7 (36%) |
| >10 | 2 (11%) |
| ICI regimen outcome | |
| Cessation due to irEnteritis | 12 (63%) |
| Cessation due to progression of malignancy | 1 (5%) |
| Cessation due to other irAEs | 4 (21%) |
| Still receiving ICI after temporary interruption | 2 (11%) |
ICI, immune checkpoint inhibitor; irAE, immune-related adverse events; irEnteritis, immune-related enteritis.